Effect of SGLT2 Inhibitor on Blood Glucose Profile in Type 2 Diabetic Patients Using Basal Insulin
NCT03631134 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2018-08-15
Summary
The change of glycemic variation and insulin dose after adding SGLT2 inhibitor in type 2 diabetic patients treated with basal insulin was observed in a single center.
Conditions
- Type2 Diabetes
Interventions
- DRUG
-
SGLT2 inhibitor
Patients will be gave SGLT2 inhibitor 10mg per day
Sponsors & Collaborators
-
Nanjing First Hospital, Nanjing Medical University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-08-15
- Primary Completion
- 2019-01-15
- Completion
- 2019-01-30
More Related Trials
-
Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
NCT06688123 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus
NCT02284269 ·Status: UNKNOWN
-
Effect of Incretin-related Drugs on Dietary Intake in Japanese Patients With Type 2 Diabetes Mellitus
NCT01568125 ·Status: UNKNOWN
-
Effect of Dihydromirycetin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes Mellitus
NCT03606694 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus Patients
NCT00349427 ·Status: COMPLETED ·Phase: PHASE3
-
SGLT2 Inhibitors and Effects on Hematopoiesis, Inflammation and Metabolic Markers
NCT05408936 ·Status: ACTIVE_NOT_RECRUITING
-
SGLT2 Inhibitors and Reducing the Risk of Cancers Among Diabetics , an Observational Study
NCT05612269 ·Status: UNKNOWN
-
Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 Diabetes
NCT03940183 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus
NCT02589639 ·Status: COMPLETED ·Phase: PHASE4
-
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
NCT00495469 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients
NCT05477017 ·Status: UNKNOWN
-
Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes
NCT06007014 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Efficacy and Safety In Poorly Controlled Type 2 Diabetics
NCT00044460 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes
NCT02964572 ·Status: COMPLETED ·Phase: NA
-
Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes
NCT02526810 ·Status: UNKNOWN ·Phase: PHASE4
-
Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients
NCT00461617 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of SGLT-2 Inhibitor in Patient With Atrial Fibrillation and Diabetes Mellitus
NCT05029115 ·Status: ENROLLING_BY_INVITATION
-
Therapies on Newly Diagnosed Type 2 Diabetes Patients With High Glucose Toxicity Which Protect Islet β Cell
NCT03180281 ·Status: UNKNOWN ·Phase: NA
-
Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients
NCT02121717 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes
NCT00856908 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes
NCT05691712 ·Status: COMPLETED ·Phase: PHASE3
-
To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes
NCT01176097 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered to Normal Healthy Male Volunteers
NCT00933062 ·Status: COMPLETED ·Phase: PHASE1
-
An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes
NCT00065312 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
NCT07018453 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2